Pembrolizumab showed an 89% objective response rate in unresectable desmoplastic melanoma, with a 37% complete response rate.

New clinical data reveals promising efficacy of VS-7375, a KRAS G12D inhibitor, in advanced lung cancer, highlighting its ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Jason Luke, MD, FACP, discusses the mechanism of action of IMA203, a novel agent for the treatment of metastatic melanoma.

A phase 3 trial showed that alpelisib plus olaparib did not reduce the risk of progression or death in relapsed/refractory ...

Trifluridine/tipiracil shows potential in improving disease-free survival in colorectal cancer patients post-surgery, despite ...

A promising allogeneic CAR-T therapy has shown the potential to succeed in ovarian cancer where standard CAR-T treatments ...

Abhinav Agrawal, MD, discusses findings from a multidisciplinary expert panel on endoscopic lung and lymph node biopsies that show how changes in biopsy methods have affected comprehensive biomarker ...

A digital app significantly enhances the quality of life for caregivers of stem cell transplant patients, reducing stress and ...

New research reveals that many patients with low-risk thyroid cancer can safely skip postoperative radioiodine ablation, ...

New analysis reveals enzalutamide significantly outperforms darolutamide in treating metastatic hormone-sensitive prostate ...

Brexu-cel demonstrated efficacy and safety even in patients with B-cell acute lymphoblastic leukemia with central nervous ...